Amrita Y. Krishnan completed her medical degree at Albany Medical College in New York as part of a combined BS-MD six-year accelerated program, where she was selected for the Alpha Omega Alpha Honor Medical Society. Her postdoctoral training comprised residency and internship in the Strong Memorial Hospital Department of Medicine at the University of Rochester, as well as fellowships at City of Hope Medical Center, Harvard Medical School Beth Israel Hospital, and the Dana Farber Cancer Institute. Dr. Krishnan is a Diplomate of the American Board of Hematology. She is also active in several professional societies. She is the former Chair of the American Society of Clinical Oncology plasma cell committee and former Co-Chair of the Center for International Blood and Marrow Transplant Research Plasma Cell Committee, and former Chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is a subcommittee member of the American Society of Hematology, American Society for Blood and Marrow Transplantation, a steering committee member for the Multiple Myeloma Research Foundation and the North American representative for the International Myeloma Foundation and is a member of the state of the science committee for ASTCT focused on defining the next generation of therapies in myeloma. Dr. Krishnan has authored almost 200 articles, abstracts, and book chapters, and she is a reviewer for several journals, including American Journal of Hematology, Bone Marrow Transplantation, Haematologica, Blood, and Biology of Blood and Marrow Transplantation. An active researcher, Dr. Krishnan was instrumental in bringing successful transplant therapy to HIV patients with lymphoma when many believed such patients were too weak to tolerate the procedure. She is currently the principal investigator of an innovative trial utilizing zinc finger nuclease–based stem cell therapy for HIV treatment. She is also the co-chair of one of the largest myeloma transplant trials in the United States evaluating the role of minimal residual disease to guide maintenance.

Mark Schroeder, MD, is Associate Professor of Medicine, Division of Oncology, Section of Blood and Marrow Transplantation at Washington University School of Medicine. Dr. Schroeder is a graduate of the University of Cincinnati College of Medicine and completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Washington University in St. Louis. He joined faculty at Washington University in 2009. He is a member of the Siteman Cancer Center and serves on the National Comprehensive Cancer Network Hematopoietic Cell Transplant Panel. Dr. Schroeder’s clinical research focuses on multiple myeloma, graft versus host disease, and stem cell transplant biology.

Dr. Ravi Vij is Jeffrey S and Prue H Distinguished Professor of Medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, where he specializes in hematologic malignancies with an academic focus on Multiple Myeloma, transplant, and cellular therapies. He also serves as Director of the Multiple Myeloma Program and as Medical Director for Satellite Operations in the Division of Oncology. Dr. Vij pursued his medical education at Maulana Azad Medical College in New Delhi, India, before completing postgraduate training in the United Kingdom. He subsequently moved to the United States, where he undertook an internal medicine residency at Rush University in Chicago, followed by fellowships in medical oncology/hematology and bone marrow transplantation at Washington University. Since joining the faculty in 2000, he has advanced through the academic ranks to full Professor of Medicine. His career has been dedicated to advancing treatment for multiple myeloma and related blood cancers. He currently serves as Senior Editor for the journal Clinical Lymphoma, Myeloma and Leukemia and has served on the Cancer and Leukemia Group B (CALGB/Alliance) Myeloma, Leukemia, and Transplant Committees, the Multiple Myeloma Research Consortium Steering Committee, Clinical Trials Network Myeloma Committee, American Society of Clinical Oncology education and scientific committees, and as Chair of the ASH Scientific Committee on Plasma Cell Dyscrasias. Dr. Vij leads a programmatic effort to further research in multiple myeloma. As the Principal Investigator for the Multiple Myeloma Tissue Banking initiative, he has fostered several collaborative efforts with laboratory researchers at Washington University to study the mutational landscape and clonal heterogeneity of multiple myeloma and its microenvironment. An active clinical investigator, Dr. Vij has led and contributed to numerous pivotal clinical trials that have shaped the modern therapeutic landscape of multiple myeloma. His research includes early development of proteasome inhibitors and immunomodulatory drugs, monoclonal antibodies, novel transplant approaches, immunotherapies including CAR-T cells, bispecific antibodies, and genomics-driven strategies. He has authored more than 300 peer-reviewed manuscripts in leading journals, including The New England Journal of Medicine, Blood, Journal of Clinical Oncology and Leukemia. Dr. Vij has mentored more than 25 fellows in clinical research, nurturing the development of future leaders in hematology and oncology. His contributions have been recognized with multiple honors, including the Multiple Myeloma Research Foundation Innovator Award, the Center of Excellence Award, and the Leukemia & Lymphoma Society Visionary of the Year Award (2023). He has also been repeatedly listed in Best Doctors in America and received the Teacher of the Year Award from the Hematology/Oncology Fellowship Program, underscoring his enduring commitment to education and mentorship.